Investigational drug · Phase 3
HMPL-760
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "HMPL-760"
First trial start
2026
Mar 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HMPL-760", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "HMPL-760" as an intervention, largest first.
- A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLPivotal-lookingRecruiting
HutchmedIndustry
NCT07409428 · 240 participants (planned) · Start Mar 20, 2026 · Primary completion Apr 30, 2028
Drug: HMPL-760; HMPL-760 Placebo and 1 more · For: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sites: Shanghai, China; Baoding, China; Beijing, China · 51 sites in all
HutchmedIndustry
NCT05190068 · 89 participants · Start Jan 4, 2022 · Primary completion Jan 27, 2025
Drug: HMPL-760 · For: B-Cell Non-Hodgkin's Lymphoma
Sites: Beijing, China; Xiameng, China; Guangzhou, China · 22 sites in all
HutchmedIndustry
NCT06601504 · 61 participants · Start Nov 5, 2024 · Primary completion May 23, 2026
Drug: HMPL-760 planned dose 1; R-GemOx and 3 more · For: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sites: Fuzhou, China; Guangzhou, China; Nanning, China · 16 sites in all
- A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 CapsulesCompleted
HutchmedIndustry
NCT07643272 · 24 participants · Start Jun 30, 2026 · Primary completion Jul 31, 2026
Drug: HMPL-760; Rabeprazole and HMPL-760 · For: Healthy Participants
Sites: Shanghai, China
HutchmedIndustry
NCT05176691 · 0 participants · Start Feb 15, 2022 · Primary completion Nov 16, 2022
Drug: HMPL-760 · For: CLL/SLL; NHL; MCL and 6 more
Sites: Anaheim, California; Atlanta, Georgia; New Orleans, Louisiana · 36 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- NSC 613327Phase 33 trials
BeBetter Med Inc · Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer, Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Ifupinostat HydrochlorideBEBT-908, CUDC-908Phase 32 trials
BeBetter Med Inc · Previously Untreated Peripheral T-Cell Lymphoma, Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.